Mapping the early stages of multiple myeloma in diverse populations
Myeloma multidimensional precancer atlas
This study is looking at how multiple myeloma, a type of blood cancer, develops from early stages in a diverse group of people, especially focusing on African Americans, to help find better ways to catch and treat the disease early.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10994712 on NIH RePORTER |
What this research studies
This research aims to create a comprehensive atlas of the early stages of multiple myeloma, a type of blood cancer that often begins with precursors like monoclonal gammopathy of undetermined significance (MGUS). By studying a large collection of samples from racially diverse cohorts, particularly focusing on African American populations, the research seeks to identify the biological changes that occur as the disease progresses from precancerous stages to full-blown multiple myeloma. The approach involves analyzing genomic and environmental factors that contribute to this transformation, which could lead to better monitoring and early intervention strategies for patients. This work is crucial for understanding the disparities in disease prevalence and outcomes among different racial groups.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with precursors to multiple myeloma, such as MGUS or smoldering myeloma, especially those from racially diverse backgrounds.
Not a fit: Patients who have already been diagnosed with advanced multiple myeloma may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and more effective treatment strategies for multiple myeloma, particularly in African American patients who are disproportionately affected.
How similar studies have performed: Previous research has shown success in identifying early biomarkers for other cancers, suggesting that this approach could yield valuable insights for multiple myeloma as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Ghobrial, Irene M. — Dana-Farber Cancer Inst
- Study coordinator: Ghobrial, Irene M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.